Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. The Role of an Interventional Program for Improving Pharmacovigilance at a Pediatric Facility.Frontiers in pharmacology · 2019
   Article
2. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.BMC medicine · 2015
   Article
3. Why drug safety should not take a back seat to efficacy.PLoS medicine · 2011
   Article
4. Key concepts of clinical trials: a narrative review.Postgraduate medicine · 2011
   Review
5. Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.BMC public health · 2011
   Article
6. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2009
   Article
7. Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada.Drug safety · 2009
   Article
8. Safety monitoring of drugs receiving pediatric marketing exclusivity.Pediatrics · 2008
   Article
9. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.PloS one · 2007
   Article
10. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).Drug safety · 2007
    Article
11. Drug safety and the media.British journal of clinical pharmacology · 2006
    Review
12. Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.Drug safety · 2005
    Review

Corrections and comments

• Commented on by
  Postmarketing surveillance--lack of vigilance, lack of trust.2004
• Commented on by
  Evaluation of suspected adverse drug reactions.2005
• Comment on
  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.2004

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as